The evaluation procedure at the Federal Joint Committee (G-BA) for the treatment of chronic wounds with cold plasma has been running for almost two years. Now the G-BA has decided in its plenary session to conduct a trial study for cold plasma therapy in chronic wounds. This is an important step on the way to reimbursement of wound treatment with cold plasma, from which about 4 million people in Germany alone could benefit.
In order for a health service to be reimbursable by the statutory health insurance funds in Germany, the Federal Joint Committee must first carry out an evaluation procedure and assess the medical and economic benefits of the therapy. For almost two years, terraplasma medical GmbH, together with market companions and leading wound experts, has been pushing the process for reimbursement of cold plasma therapy at the G-BA. The decision to conduct a trial study represents the most important milestone.
All participants in the plenary session at the G-BA agreed that cold plasma can positively influence the healing process of chronic wounds and will improve the quality of life of many people. In the next few months, the G-BA will decide on the exact design of the study and then conduct the trial. In addition to inpatient treatment, the transsectoral treatment of chronic wounds in the office-based and outpatient sector is the focus of the study. Especially there, our plasma care®, as the only mobile cold plasma device that generates the cold plasma directly from the ambient air and does not require any additional gas, offers the optimal treatment.
Enormous potential in Germany
According to current estimates, up to 4 million of the more than 70 million people insured under the statutory health insurance system suffer from chronic wounds. Many of these wounds are not treated optimally and can benefit from treatment with cold plasma.
Like many wound experts, terraplasma medical GmbH is also pleased about the G-BA’s decision, which is a very positive signal and an essential step for plasma therapy. If treatment with cold plasma becomes part of the standard care of chronic wounds in the future, we expect 30-40 million plasma treatments per year.
Many studies and application observations already show how successful treatment with plasma care® is. As a co-payment service and especially for privately insured patients, more and more doctors and wound managers are already offering therapy with plasma care® – and thus improving the quality of life of their patients.
Here you can read all the details of the G-BA’s decision: https://www.g-ba.de/beschluesse/5889/